TMC207: the first compound of a new class of potent anti- tuberculosis drugs

A paper providing an analysis of TMC207, a first-in-class diarylquinoline compound with a novel mechanism of action, the inhibition of bacterial ATP synthase, and potent activity against drug-sensitive and drug-resistant TB.

Document Date: 1 June, 2010
Author: Alberto Matteelli and others